• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

    10/20/25 12:30:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader researcher community

    PLEASANTON, Calif., Oct. 20, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, and Anthropic, an AI safety and research company and creator of Claude, today announced a collaboration integrate 10x's analysis tools into the newly-launched Claude for Life Sciences offering the Model Context Protocol (MCP), a standard protocol that connects specialized tools to AI systems. This collaboration makes 10x's single cell and spatial biology capabilities accessible through natural language, enabling scientists to explore complex datasets conversationally rather than through code.

    10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

    Accessing 10x's single cell and spatial analysis capabilities has traditionally required computational expertise - from writing command-line scripts to managing high-performance computing systems. Now, these same tools can respond to questions asked in plain English. Using Claude, researchers can now perform common analytical tasks - including aligning reads, generating Feature Barcode matrices, performing clustering and other secondary analysis - through a conversational interface that complements traditional computational workflows, making it faster and easier for researchers to engage directly with their data. 

    "Our collaboration with Anthropic makes the power of single cell and spatial biology accessible to every scientist through Claude for Life Sciences," said Serge Saxonov, Co-Founder and CEO of 10x Genomics. "Now, researchers can begin to interact with their data through natural conversation, without needing a computational background. By removing the technical barriers, we're enabling scientists to focus on discovery and accelerate breakthroughs. This is just the first step toward making complex analysis as intuitive as asking one question - and expanding what's possible in biological research."

    With this launch, researchers can now use Claude for Life Sciences to interact directly with their own 10x datasets. By integrating 10x's Cloud Analysis, Claude lowers the barrier to entry for new users and scales to meet the needs of large-scale analyses for advanced research teams. These use cases demonstrate how conversational interfaces can simplify exploration and accelerate insights across a wide range of research settings.

    "The future of biological research is a partnership between human expertise and AI-powered capabilities. Our collaboration with 10x Genomics demonstrates what's possible when we remove the technical barriers that have limited access to the analysis tools that labs run on," said Eric Kauderer-Abrams, Head of Life Sciences and Biology, Anthropic. "Through Claude for Life Sciences, tasks that traditionally required computational expertise, can now happen through natural conversation. When we enable human expertise and AI to work together across the scientific process—from hypothesis generation to data interpretation to publication—we can accelerate discovery and progress against disease."

    The collaboration marks the beginning of a broader effort to make 10x single cell and spatial analysis more intuitive and accessible through AI. For more information, visit https://claude.com/solutions/life-sciences.

    About 10x Genomics

    10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

    About Anthropic

    Anthropic is an AI research and development company that creates reliable, interpretable, and steerable AI systems. Anthropic's flagship product is Claude, a large language model trusted by millions of users worldwide. Anthropic's flagship product is Claude, a family of foundational AI models purpose-built for business tasks. Visit www.anthropic.com for more information.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended March 31, 2025 and 10-K for the fiscal year ended December 31, 2024 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

    Disclosure Information

    10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

    Contacts

    Investors: [email protected]

    Media: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-and-anthropic-partner-to-make-single-cell-and-spatial-analysis-more-accessible-through-claude-for-life-sciences-302588055.html

    SOURCE 10x Genomics, Inc.

    Get the next $TXG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    9/11/2025$15.00Neutral
    Piper Sandler
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences

    Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader researcher community PLEASANTON, Calif., Oct. 20, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, and Anthropic, an AI safety and research company and creator of Claude, today announced a collaboration integrate 10x's analysis tools into the newly-launched Claude for Life Sciences offering the Model Context Protocol (MCP), a standard protocol that connects specialized tools to AI systems. This collaboration makes 10x's single cell and spatial b

    10/20/25 12:30:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

    PLEASANTON, Calif., Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    10/9/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

    Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path for Blood Disorder Diagnosis, complementing bone marrow procedures PLEASANTON, Calif. and REHOVOT, Israel, Sept. 9, 2025 /PRNewswire/ -- CLISEQ Ltd., a translational diagnostics company spun out of Yeda, the commercial arm of the Weizmann Institute of Science, today announced a translational research collaboration with 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology and the Weizmann Institute. Together, the organizations are launching a multi-year, international clinical research study to investigate the use of peripheral single c

    9/9/25 9:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on 10x Genomics with a new price target

    Piper Sandler initiated coverage of 10x Genomics with a rating of Neutral and set a new price target of $15.00

    9/11/25 8:40:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

    2/13/25 7:11:34 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Leerink Partners initiated coverage on 10x Genomics with a new price target

    Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00

    9/3/24 8:15:17 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    SEC Filings

    View All

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 144 filed by 10x Genomics Inc.

    144 - 10x Genomics, Inc. (0001770787) (Subject)

    8/22/25 4:26:28 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SCHEDULE 13G filed by 10x Genomics Inc.

    SCHEDULE 13G - 10x Genomics, Inc. (0001770787) (Subject)

    8/13/25 9:10:23 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

    SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    8/12/25 4:20:13 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Saxonov Serge gifted 900 shares, decreasing direct ownership by 0.09% to 1,034,817 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    9/16/25 4:37:26 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Saxonov Serge sold $128,881 worth of shares (9,348 units at $13.79), decreasing direct ownership by 0.98% to 945,892 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    8/26/25 4:15:30 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Taich Adam sold $307,657 worth of shares (22,315 units at $13.79), decreasing direct ownership by 7% to 309,273 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    8/26/25 4:14:27 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    8/8/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care

    ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

    Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

    1/10/22 8:00:00 AM ET
    $RARE
    $TXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Financials

    Live finance-specific insights

    View All

    10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

    PLEASANTON, Calif., Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    10/9/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports Second Quarter 2025 Financial Results

    PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter.Entered into a definitive agreement to acquire Scale Biosc

    8/7/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025

    PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the second quarter ended June 30, 2025 after market close on Thursday, August 7, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    7/10/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/8/24 2:46:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

    SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    10/4/24 2:14:32 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials